Reductions in Mean 24-Hour Ambulatory Blood Pressure After 6-Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension

Journal of Clinical Hypertension

Volumn 18, Issue 1, 2016, Pages 43-52

  Townsend, Raymond R ^a   Machin, Israel ^b   Ren, Jimmy ^c   Trujillo, Angelina ^d   Kawaguchi, Masato ^e   Vijapurkar, Ujjwala ^c   Damaraju, Chandrasekharrao V ^c   Pfeifer, Michael ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Canvas Clinical Research   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d MD LLC   (United States)

^e JCHO Yufuin Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; CREATININE; GLYCOSYLATED HEMOGLOBIN; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSMOTIC DIURESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY;

BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED;

EID: 84953638180     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12747     Document Type: Article

References (34)

1. Kabakov E, Norymberg C, Osher E, et al. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. J Cardiometab Syndr. 2006;1:95-101.
2. Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012;380:601-610.
3. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262-274.
4. Rosenthal N, Meininger G, Ways K, et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci. 2015; doi: 10.1111/nyas.12852 [Epub ahead of print].
5. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8:262-275.
6. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16:875-882.
7. Sha S, Polidori D, Heise T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:1087-1095.
8. Saulsberry WJ, Coleman CI, Mearns ES, et al. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes. Int J Clin Pract. 2015;69:1221-1235.
9. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941-950.
10. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
11. Stenlöf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-382.
12. NCT01939496. Evaluation of blood pressure reduction, safety, and tolerability of canagliflozin in patients with hypertension and type 2 diabetes mellitus on stable doses of anti-hyperglycemic and anti-hypertensive agents. http://www.clinicaltrials.gov. Accessed September 21, 2015.
13. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-591.
14. Tikkanen I, Narko K, Zeller C, et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38:420-428.
15. Chilton R, Tikkanen I, Cannon CP, et al. The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type 2 diabetes. J Hypertens. 2015;33(suppl 1):e53.
16. Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
17. Sjöström CD, Johansson P, Ptaszynska A, et al. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res. 2015;12:352-358.
18. Amin NB, Wang X, Mitchell JR, et al. Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab. 2015;17:805-808.
19. Maliha G, Townsend RR. SGLT2 inhibitors: their potential reduction in blood pressure. J Am Soc Hypertens. 2015;9:48-53.
20. Majewski C, Bakris G. Blood pressure reduction: an added benefit of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429-430.
21. Cefalu WT, Stenlöf K, Leiter LA, et al. Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes. Diabetologia. 2015;58:1183-1187.
22. Han Y, Cho Y-E, Ayon R. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am J Physiol Lung Cell Mol Physiol. 2015;309:L1027-L1036.
23. Asmar R, Safar M, Queneau P. Evaluation of the placebo effect and reproducibility of blood pressure measurement in hypertension. Am J Hypertens. 2001;14:546-552.
24. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med. 2006;354:2368-2374.
25. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
26. Black HR. The paradigm has shifted, to systolic blood pressure. Hypertension. 1999;34:386-387.
27. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med. 2003;138:10-16.
28. Strandberg TE, Pitkala K. What is the most important component of blood pressure: systolic, diastolic or pulse pressure? Curr Opin Nephrol Hypertens. 2003;12:293-297.
29. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539-545.
30. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-149.
31. Brunton SA. The potential role of sodium glucose co-transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus. Int J Clin Pract. 2015;69:1071-1087.
32. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; doi 10.1056/NEJMoa1504720 [Epub ahead of print].
33. Neal B, Perkovic V, de Zeeuw D, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes. Diabetes Care. 2015;38:403-411.
34. A study of the effects of canagliflozin (JNJ-28431754) on renal endpoints in adult participants with type 2 diabetes mellitus (CANVAS-R). Study protocol NCT01989754. http://www.clinicaltrials.gov. Accessed September 21, 2015.